Black Book: Fortified Health top cybersecurity provider for medical devices

Black Book Market Research, a healthcare and public opinion research company, has named Fortified Health Security as the top cybersecurity service vendor in the "medical device and internet of things" category.

Black Book surveyed 2,464 cybersecurity professionals from over 680 organizations to identify vulnerabilities healthcare systems face when it came to cyberattacks. With 96 percent of information technology experts reporting hackers have exploited healthcare’s vulnerability, professionals are hoping to strengthen security.

“We know that many healthcare organizations do not have the staff, or expertise, to prepare for and address cybersecurity issues which is why we offer programs that scale from a technology-enabled service to a fully managed solution depending on the organization’s needs and infrastructure,” said Dan L. Dodson, President of Fortified Health Security. “Our Connected Medical Device & IoT Security Program is in demand by many hospitals and health systems because of the immediate positive impact it provides to their security posture and this recognition by Black Book reflects the importance of this program.”

Read more at the link below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.